Literature DB >> 22187281

Accelerating identification and regulatory approval of investigational cancer drugs.

Laura J Esserman1, Janet Woodcock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22187281     DOI: 10.1001/jama.2011.1837

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  22 in total

1.  The biomarkers consortium.

Authors:  David Wholley
Journal:  Nat Rev Drug Discov       Date:  2014-11       Impact factor: 84.694

2.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Authors:  Hope S Rugo; Olufunmilayo I Olopade; Angela DeMichele; Christina Yau; Laura J van 't Veer; Meredith B Buxton; Michael Hogarth; Nola M Hylton; Melissa Paoloni; Jane Perlmutter; W Fraser Symmans; Douglas Yee; A Jo Chien; Anne M Wallace; Henry G Kaplan; Judy C Boughey; Tufia C Haddad; Kathy S Albain; Minetta C Liu; Claudine Isaacs; Qamar J Khan; Julie E Lang; Rebecca K Viscusi; Lajos Pusztai; Stacy L Moulder; Stephen Y Chui; Kathleen A Kemmer; Anthony D Elias; Kirsten K Edmiston; David M Euhus; Barbara B Haley; Rita Nanda; Donald W Northfelt; Debasish Tripathy; William C Wood; Cheryl Ewing; Richard Schwab; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Donald A Berry; Laura J Esserman
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

3.  Adaptive Randomization of Neratinib in Early Breast Cancer.

Authors:  John W Park; Minetta C Liu; Douglas Yee; Christina Yau; Laura J van 't Veer; W Fraser Symmans; Melissa Paoloni; Jane Perlmutter; Nola M Hylton; Michael Hogarth; Angela DeMichele; Meredith B Buxton; A Jo Chien; Anne M Wallace; Judy C Boughey; Tufia C Haddad; Stephen Y Chui; Kathleen A Kemmer; Henry G Kaplan; Claudine Isaacs; Rita Nanda; Debasish Tripathy; Kathy S Albain; Kirsten K Edmiston; Anthony D Elias; Donald W Northfelt; Lajos Pusztai; Stacy L Moulder; Julie E Lang; Rebecca K Viscusi; David M Euhus; Barbara B Haley; Qamar J Khan; William C Wood; Michelle Melisko; Richard Schwab; Teresa Helsten; Julia Lyandres; Sarah E Davis; Gillian L Hirst; Ashish Sanil; Laura J Esserman; Donald A Berry
Journal:  N Engl J Med       Date:  2016-07-07       Impact factor: 91.245

Review 4.  Comorbidity in older adults with cancer.

Authors:  Grant R Williams; Amy Mackenzie; Allison Magnuson; Rebecca Olin; Andrew Chapman; Supriya Mohile; Heather Allore; Mark R Somerfield; Valerie Targia; Martine Extermann; Harvey Jay Cohen; Arti Hurria; Holly Holmes
Journal:  J Geriatr Oncol       Date:  2015-12-22       Impact factor: 3.599

Review 5.  Biomarkers of residual disease after neoadjuvant therapy for breast cancer.

Authors:  Frederique Penault-Llorca; Nina Radosevic-Robin
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

6.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 7.  The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Authors:  Adam L Boxer; Michael Gold; Edward Huey; William T Hu; Howard Rosen; Joel Kramer; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; George Jackson; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven S Khachaturian; Margaret Sutherland; Susan Abushakra; Joseph Lewcock; Robert Farese; Robert O Kenet; Frank Laferla; Steve Perrin; Steve Whitaker; Lawrence Honig; Marsel M Mesulam; Brad Boeve; Murray Grossman; Bruce L Miller; Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2012-10-10       Impact factor: 21.566

Review 8.  Developing safety criteria for introducing new agents into neoadjuvant trials.

Authors:  Angela DeMichele; Donald A Berry; JoAnne Zujewski; Sally Hunsberger; Larry Rubinstein; Joseph E Tomaszewski; Gary Kelloff; Jane Perlmutter; Meredith Buxton; Julia Lyandres; Kathy S Albain; Chris Benz; A Jo Chien; Paul Haluska; Brian Leyland-Jones; Minetta C Liu; Pamela Munster; Olufunmilayo Olopade; John W Park; Barbara A Parker; Lajos Pusztai; Debu Tripathy; Hope Rugo; Douglas Yee; Laura Esserman
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

Review 9.  An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity.

Authors:  Aaron Boudreau; Laura J van't Veer; Mina J Bissell
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

Review 10.  Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

Authors:  Benjamin Carlisle; Nadine Demko; Georgina Freeman; Amanda Hakala; Nathalie MacKinnon; Tim Ramsay; Spencer Hey; Alex John London; Jonathan Kimmelman
Journal:  J Natl Cancer Inst       Date:  2015-11-07       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.